dwb2023/gtopdb-target-family-interaction-detail huggingface dataset:
Target family: Folate biosynthesis enzymes (type: other_protein)
Target: Plasmodium falciparum bifunctional dihydrofolate reductase-thymidylate synthase

Ligand: cycloguanil (Synthetic organic)
Interaction type: None
Action: None
Ligand approved: no
Primary target: no
Median affinity: 8.770000457763672 pIC50
Reference (Journal): The activities of current antimalarial drugs on the life cycle stages of Plasmodium: a comparative study with human and rodent parasites.
Published in: PLoS Med

Ligand: cycloguanil (Synthetic organic)
Interaction type: None
Action: None
Ligand approved: no
Primary target: no
Median affinity: 6.440000057220459 pIC50
Reference (Journal): The activities of current antimalarial drugs on the life cycle stages of Plasmodium: a comparative study with human and rodent parasites.
Published in: PLoS Med

Ligand: cycloguanil (Synthetic organic)
Interaction type: None
Action: None
Ligand approved: no
Primary target: no
Median affinity: 6 pIC50
Reference (Journal): The activities of current antimalarial drugs on the life cycle stages of Plasmodium: a comparative study with human and rodent parasites.
Published in: PLoS Med

Ligand: cycloguanil (Synthetic organic)
Interaction type: None
Action: None
Ligand approved: no
Primary target: no
Median affinity: 6.349999904632568 pIC50
Reference (Journal): The activities of current antimalarial drugs on the life cycle stages of Plasmodium: a comparative study with human and rodent parasites.
Published in: PLoS Med

Ligand: P218 (Synthetic organic)
Interaction type: None
Action: None
Ligand approved: no
Primary target: no
Median affinity: 7.349999904632568 pEC50
Reference (Journal): A comprehensive model for assessment of liver stage therapies targeting Plasmodium vivax and Plasmodium falciparum.
Published in: Nat Commun
Target family: Formylpeptide receptors (type: gpcr)
Target: FPR3

Ligand: F2L (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pEC50
Reference (Journal): Identification and characterization of an endogenous chemotactic ligand specific for FPRL2.
Published in: J Exp Med

Ligand: annexin I-(2-26) (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pEC50
Reference (Journal): An annexin 1 N-terminal peptide activates leukocytes by triggering different members of the formyl peptide receptor family.
Published in: J Immunol
Target family: Formylpeptide receptors (type: gpcr)
Target: FPR2

Ligand: WRWWWW (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 6.639999866485596 pIC50
Reference (Journal): Identification of peptides that antagonize formyl peptide receptor-like 1-mediated signaling.
Published in: J Immunol

Ligand: WKYMVm (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 10.13 pKd
Reference (Journal): The synthetic peptide Trp-Lys-Tyr-Met-Val-Met-NH2 specifically activates neutrophils through FPRL1/lipoxin A4 receptors and is an agonist for the orphan monocyte-expressed chemoattractant receptor FPRL2.
Published in: J Biol Chem

Ligand: WKYMVm (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 10.13 pKd
Reference (Journal): Functional characterization of three mouse formyl peptide receptors.
Published in: Mol Pharmacol

Ligand: WKYMVm (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pEC50
Reference (Journal): The synthetic peptide Trp-Lys-Tyr-Met-Val-D-Met is a potent chemotactic agonist for mouse formyl peptide receptor.
Published in: J Immunol

Ligand: WKYMVm (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pEC50
Reference (Journal): Functional characterization of three mouse formyl peptide receptors.
Published in: Mol Pharmacol
Target family: Formylpeptide receptors (type: gpcr)
Target: FPR3

Ligand: WRWWWW (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 6 pIC50
Reference (Journal): Trp-Arg-Trp-Trp-Trp-Trp antagonizes formyl peptide receptor like 2-mediated signaling.
Published in: Biochem Biophys Res Commun

Ligand: WKYMVm (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 8.52 pEC50
Reference (Journal): The synthetic peptide Trp-Lys-Tyr-Met-Val-Met-NH2 specifically activates neutrophils through FPRL1/lipoxin A4 receptors and is an agonist for the orphan monocyte-expressed chemoattractant receptor FPRL2.
Published in: J Biol Chem
Target family: Formylpeptide receptors (type: gpcr)
Target: FPR2

Ligand: WKYMVm (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 10.13 pKd
Reference (Journal): Utilization of two seven-transmembrane, G protein-coupled receptors, formyl peptide receptor-like 1 and formyl peptide receptor, by the synthetic hexapeptide WKYMVm for human phagocyte activation.
Published in: J Immunol
Target family: Formylpeptide receptors (type: gpcr)
Target: FPR3

Ligand: LXA4 (Metabolite)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 8.82 pKd
Reference (Journal): Aspirin-triggered 15-epi-lipoxin A4 (LXA4) and LXA4 stable analogues are potent inhibitors of acute inflammation: evidence for anti-inflammatory receptors.
Published in: J Exp Med

Ligand: humanin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 8.95 pEC50
Reference (Journal): N-Formylated humanin activates both formyl peptide receptor-like 1 and 2.
Published in: Biochem Biophys Res Commun

Ligand: Hp(2-20) (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 5 pEC50
Reference (Journal): A proinflammatory peptide from Helicobacter pylori activates monocytes to induce lymphocyte dysfunction and apoptosis.
Published in: J Clin Invest

Ligand: fMet-Met-Tyr-Ala-Leu-Phe (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 6 pEC50
Reference (Journal): Human mitochondria-derived N-formylated peptides are novel agonists equally active on FPR and FPRL1, while Listeria monocytogenes-derived peptides preferentially activate FPR.
Published in: Eur J Immunol

Ligand: F2L-[125I]Tyr (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 8 pKd
Reference (Journal): Identification and characterization of an endogenous chemotactic ligand specific for FPRL2.
Published in: J Exp Med
Target family: Formylpeptide receptors (type: gpcr)
Target: FPR1

Ligand: methionine benzimidazole 6 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 6.3 pIC50
Reference (Journal): Discovery of small molecule human FPR1 receptor antagonists.
Published in: Bioorg Med Chem Lett

Ligand: i-Boc-Met-Leu-Phe (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 6.6 pIC50
Reference (Journal): Selective inhibition of N-formylpeptide-induced neutrophil activation by carbamate-modified peptide analogues.
Published in: Biochemistry

Ligand: group E 1682-2106 [PMID:16118363] (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 5.3 pIC50
Reference (Journal): Integration of virtual screening with high-throughput flow cytometry to identify novel small molecule formylpeptide receptor antagonists.
Published in: Mol Pharmacol

Ligand: gG-2p20 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pEC50
Reference (Journal): A proinflammatory peptide from herpes simplex virus type 2 glycoprotein G affects neutrophil, monocyte, and NK cell functions.
Published in: J Immunol

Ligand: fMet-Met-Tyr-Ala-Leu-Phe (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 8 pEC50
Reference (Journal): Human mitochondria-derived N-formylated peptides are novel agonists equally active on FPR and FPRL1, while Listeria monocytogenes-derived peptides preferentially activate FPR.
Published in: Eur J Immunol

Ligand: fMet-Met-Tyr-Ala-Leu-Phe (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 10 pEC50
Reference (Journal): Functional characterization of three mouse formyl peptide receptors.
Published in: Mol Pharmacol

Ligand: fMet-Met-Trp-Leu-Leu (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 9 pEC50
Reference (Journal): Tethered ligand library for discovery of peptide agonists.
Published in: J Biol Chem

Ligand: fMet-Leu-Phe-Ile-Ile-Lys-FITC (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 8.6 pKd
Reference (Journal): Functional characterization of three mouse formyl peptide receptors.
Published in: Mol Pharmacol
Target family: FRAY subfamily (type: enzyme)
Target: serine/threonine kinase 39

Ligand: aplithianine A (Natural product)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.460000038146973 pIC50
Reference (Journal): Discovery and Synthesis of a Naturally Derived Protein Kinase Inhibitor that Selectively Inhibits Distinct Classes of Serine/Threonine Kinases.
Published in: J Nat Prod
Target family: FRAY subfamily (type: enzyme)
Target: oxidative stress responsive kinase 1

Ligand: compound 74 [PMID: 24793884] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Synthesis and structure-activity relationship of trisubstituted thiazoles as Cdc7 kinase inhibitors.
Published in: Eur J Med Chem
Target family: Free fatty acid receptors (type: gpcr)
Target: FFA2 receptor

Ligand: propanoic acid (Metabolite)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pEC50
Reference (Journal): The Orphan G protein-coupled receptors GPR41 and GPR43 are activated by propionate and other short chain carboxylic acids.
Published in: J Biol Chem

Ligand: (S)-4-CMTB (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity: 6.400000095367432 pEC50
Reference (Journal): Identification and functional characterization of allosteric agonists for the G protein-coupled receptor FFA2.
Published in: Mol Pharmacol

Ligand: (S)-4-CMTB (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity: 6.400000095367432 pEC50
Reference (Journal): Extracellular ionic locks determine variation in constitutive activity and ligand potency between species orthologs of the free fatty acid receptors FFA2 and FFA3.
Published in: J Biol Chem

Ligand: TUG-1375 (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: yes
Median affinity: 6.690000057220459 pKi
Reference (Journal): Discovery of a Potent Thiazolidine Free Fatty Acid Receptor 2 Agonist with Favorable Pharmacokinetic Properties.
Published in: J Med Chem

Ligand: TUG-1375 (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: yes
Median affinity: 6.099999904632568 pEC50
Reference (Journal): Discovery of a Potent Thiazolidine Free Fatty Acid Receptor 2 Agonist with Favorable Pharmacokinetic Properties.
Published in: J Med Chem

Ligand: TUG-1375 (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 6.440000057220459 pEC50
Reference (Journal): Discovery of a Potent Thiazolidine Free Fatty Acid Receptor 2 Agonist with Favorable Pharmacokinetic Properties.
Published in: J Med Chem

Ligand: TUG-1375 (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: yes
Median affinity: 7.110000133514404 pEC50
Reference (Journal): Discovery of a Potent Thiazolidine Free Fatty Acid Receptor 2 Agonist with Favorable Pharmacokinetic Properties.
Published in: J Med Chem

Ligand: TUG-2304 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 8.460000038146973 pIC50
Reference (Journal): Discovery of Potent Tetrazole Free Fatty Acid Receptor 2 Antagonists
Published in: J. Med. Chem.

Ligand: TUG-2304 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 8.350000381469727 pIC50
Reference (Journal): Discovery of Potent Tetrazole Free Fatty Acid Receptor 2 Antagonists
Published in: J. Med. Chem.
Target family: Free fatty acid receptors (type: gpcr)
Target: FFA2 receptor

Ligand: propanoic acid (Metabolite)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pEC50
Reference (Journal): Selective orthosteric free fatty acid receptor 2 (FFA2) agonists: identification of the structural and chemical requirements for selective activation of FFA2 versus FFA3.
Published in: J Biol Chem
Target family: Free fatty acid receptors (type: gpcr)
Target: FFA4 receptor

Ligand: TUG-1197 (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 6.630000114440918 pEC50
Reference (Journal): Non-Acidic Free Fatty Acid Receptor 4 Agonists with Antidiabetic Activity.
Published in: J Med Chem

Ligand: TUG-1197 (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 6.829999923706055 pEC50
Reference (Journal): Non-Acidic Free Fatty Acid Receptor 4 Agonists with Antidiabetic Activity.
Published in: J Med Chem

Ligand: TUG-891 (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 7 pEC50
Reference (Journal): Discovery of a potent and selective GPR120 agonist.
Published in: J Med Chem
Target family: GABA<sub>A</sub> receptors (type: lgic)
Target: GABA<sub>A</sub> receptor &alpha;1 subunit

Ligand: [3H]flunitrazepam (Synthetic organic)
Interaction type: Allosteric modulator
Action: Positive
Ligand approved: no
Primary target: no
Median affinity:  -
Target family: GABA<sub>A</sub> receptors (type: lgic)
Target: GABA<sub>A</sub> receptor &alpha;3 subunit

Ligand: zolpidem (Synthetic organic)
Interaction type: Allosteric modulator
Action: Positive
Ligand approved: yes
Approval source: FDA (1992)
Primary target: no
Median affinity: 5.670000076293945 pKi
Reference (Journal): Cloning of cDNA sequences encoding human alpha 2 and alpha 3 gamma-aminobutyric acidA receptor subunits and characterization of the benzodiazepine pharmacology of recombinant alpha 1-, alpha 2-, alpha 3-, and alpha 5-containing human gamma-aminobutyric acidA receptors.
Published in: Mol Pharmacol

Ligand: Zn2+ (Inorganic)
Interaction type: Allosteric modulator
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity:  -
Target family: GABA<sub>A</sub> receptors (type: lgic)
Target: GABA<sub>A</sub> receptor &alpha;5 subunit

Ligand: [3H]flunitrazepam (Synthetic organic)
Interaction type: Allosteric modulator
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: [3H]gabazine (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: [3H]L655708 (Synthetic organic)
Interaction type: Allosteric modulator
Action: Inverse agonist
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: [3H]muscimol (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: [3H]RY80 (Synthetic organic)
Interaction type: None
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 9.199999809265137 pKd
Reference (Journal): [3H]RY 80: A high-affinity, selective ligand for gamma-aminobutyric acidA receptors containing alpha-5 subunits.
Published in: J Pharmacol Exp Ther

Ligand: TBPS (Synthetic organic)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: tetrahydrodeoxycorticosterone (Metabolite)
Interaction type: Allosteric modulator
Action: Potentiation
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: TP003 (Synthetic organic)
Interaction type: Allosteric modulator
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: TPA023 (Synthetic organic)
Interaction type: Allosteric modulator
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: triazolam (Synthetic organic)
Interaction type: Allosteric modulator
Action: Positive
Ligand approved: yes
Approval source: FDA (1982)
Primary target: yes
Median affinity: 8.399999618530273 pKd
Reference (Journal): Selective influence on contextual memory: physiochemical properties associated with selectivity of benzodiazepine ligands at GABAA receptors containing the alpha5 subunit.
Published in: J Med Chem
Target family: GABA<sub>A</sub> receptors (type: lgic)
Target: GABA<sub>A</sub> receptor &rho;2 subunit

Ligand: picrotoxin (Natural product)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Primary target: no
Median affinity:  -
Target family: GABA<sub>A</sub> receptors (type: lgic)
Target: GABA<sub>A</sub> receptor &alpha;5 subunit

Ligand: ZK93423 (Synthetic organic)
Interaction type: Agonist
Action: Partial agonist
Ligand approved: no
Primary target: no
Median affinity: 8.399999618530273 pKi
Reference (Journal): Synthesis and evaluation of analogues of the partial agonist 6-(propyloxy)-4-(methoxymethyl)-beta-carboline-3-carboxylic acid ethyl ester (6-PBC) and the full agonist 6-(benzyloxy)-4-(methoxymethyl)-beta-carboline-3-carboxylic acid ethyl ester (Zk 93423) at wild type and recombinant GABAA receptors.
Published in: J Med Chem

Ligand: ZK93426 (Synthetic organic)
Interaction type: Allosteric modulator
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: Zn2+ (Inorganic)
Interaction type: Allosteric modulator
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity:  -
Target family: GABA<sub>A</sub> receptors (type: lgic)
Target: GABA<sub>A</sub> receptor &gamma;3 subunit

Ligand: TBPS (Synthetic organic)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: picrotoxin (Natural product)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Primary target: no
Median affinity:  -
Target family: GABA<sub>A</sub> receptors (type: lgic)
Target: GABA<sub>A</sub> receptor &gamma;2 subunit

Ligand: TBPS (Synthetic organic)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Primary target: no
Median affinity:  -
Target family: GABA<sub>A</sub> receptors (type: lgic)
Target: GABA<sub>A</sub> receptor &theta; subunit

Ligand: TBPS (Synthetic organic)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: picrotoxin (Natural product)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Primary target: no
Median affinity:  -
Target family: GABA<sub>A</sub> receptors (type: lgic)
Target: GABA<sub>A</sub> receptor &rho;3 subunit

Ligand: TPMPA (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: TBPS (Synthetic organic)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: (±)-cis-2-CAMP (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: piperidine-4-sulphonic acid (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: picrotoxin (Natural product)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: muscimol (Natural product)
Interaction type: Agonist
Action: Partial agonist
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: trans-3-ACPBPA (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: isonipecotic acid (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: isoguvacine (Synthetic organic)
Interaction type: Agonist
Action: Partial agonist
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: cis-3-ACPBPA (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Primary target: no
Median affinity:  -

Ligand: gaboxadol (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Aza-THIP and related analogues of THIP as GABA C antagonists.
Published in: Bioorg Med Chem
Target family: GABA<sub>A</sub> receptors (type: lgic)
Target: GABA<sub>A</sub> receptor &alpha;6 subunit

Ligand: [3H]CGS8216 (Synthetic organic)
Interaction type: Allosteric modulator
Action: Mixed
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: [3H]gabazine (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: [3H]muscimol (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: [3H]Ro154513 (Synthetic organic)
Interaction type: Allosteric modulator
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: TBPS (Synthetic organic)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: tetrahydrodeoxycorticosterone (Metabolite)
Interaction type: Allosteric modulator
Action: Potentiation
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: Zn2+ (Inorganic)
Interaction type: Allosteric modulator
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity:  -
Target family: GABA<sub>A</sub> receptors (type: lgic)
Target: GABA<sub>A</sub> receptor &beta;1 subunit

Ligand: picrotoxin (Natural product)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: TBPS (Synthetic organic)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Primary target: no
Median affinity:  -
Target family: GABA<sub>A</sub> receptors (type: lgic)
Target: GABA<sub>A</sub> receptor &beta;2 subunit

Ligand: picrotoxin (Natural product)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: TBPS (Synthetic organic)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Primary target: no
Median affinity:  -
Target family: GABA<sub>A</sub> receptors (type: lgic)
Target: GABA<sub>A</sub> receptor &beta;3 subunit

Ligand: etazolate (Synthetic organic)
Interaction type: Allosteric modulator
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 5.460000038146973 pIC50
Reference (Journal): Interaction of allosteric ligands with GABAA receptors containing one, two, or three different subunits.
Published in: Eur J Pharmacol

Ligand: picrotoxin (Natural product)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: TBPS (Synthetic organic)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Primary target: no
Median affinity:  -